cber cber 510(k) issues sheryl a. kochman, mt(ascp) chief, devices review branch dba/obrr/cber ivd...
TRANSCRIPT
CC BBEE RR
CBER 510(k) Issues
Sheryl A. Kochman, MT(ASCP)
Chief, Devices Review Branch
DBA/OBRR/CBER
IVD Roundtable – OIVD Workshop April 23, 2003
CC BBEE RR
Why does CBER review devices? Jurisdiction for medical device review
is governed by the FDA Intercenter Agreement between the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) (October 31, 1991)
Available at:
http://www.fda.gov/cber/dap/devpubs.htm
CC BBEE RR
Intercenter Agreement Between CBER and CDRH (October 31, 1991)
CBER will have the lead responsibility for regulating medical devices used or indicated for the collection, processing, testing, storage, or administration of biological products (including blood products, blood components, or analogous products), and will use authorities under the Public Health Service Act (PHS Act) and the FD&C Act, as well as any other authorities delegated to it, as appropriate.
CC BBEE RR
Intercenter Agreement (cont)
In vitro tests which are required for blood donor screening and related blood banking practices (such as donor re-entry) are licensed under the PHS Act
Immunohematology Reagents
• Blood Grouping Reagents
• Reagent Red Blood Cells
• Antihuman Globulins
Limulus amebocyte lysate (LAL)
Blood Borne pathogen tests*• HIV 1/2• HIV Ag• HBsAg• HB core• HCV• HTLV I/II
* examples only, not a complete list
CC BBEE RR
Intercenter Agreement (cont)
CBER also has the responsibility for regulating all in vitro diagnostic tests and any other medical devices intended for use for human immunodeficiency virus, type 1 (HIV 1) and type 2 (HIV 2) and other retroviruses.
These devices, including but not limited to collection devices, specimen containers, test kit components or support materials and those used or indicated for the inactivation of these viruses, will be regulated by CBER under the Medical Device Authorities (MDA).
CC BBEE RR
What devices does CBER review ?* Medical devices that are dedicated systems intended for use
in collection, processing, or administration of a licensed biological or analogous productIncludes
• Apheresis machines Blood Warmers• Filters Plasma Thawers• Refrigerators Stem Cell Concentrator
Excludes • Administration sets• Therapeutic devices
Dialysis machinesIntraoperative blood salvage devices
* As stated in the Intercenter Agreement
CC BBEE RR
Devices Reviewed at CBER (cont)*Certain In Vitro ReagentsThose intended for use in the processing of
licensed biologicals and analogous productsLectinsProtectinsBovine albumin potentiating media
Leukocyte typing sera or other medical devices intended for use in the determination of tissue type
Quality assurance reagents intended for use in conjunction with a licensed biological reagents or in vitro tests
CC BBEE RR
Devices Reviewed at CBER (cont)* Medical devices other than reagents intended for
use in the preparation of, in conjunction with, or for the quality assurance of a blood bank related licensed biological product or practice.Clinical laboratory devices with separate
blood bank claimsSoftware programs for data management in a
blood establishment Dosimeters and thermal indicatorsMicrowave ovens used for thawing blood
products
CC BBEE RR
Devices Reviewed at CBER (cont) See also
21 CFR 864.9050 through 864.9875List of Devices Regulated by CBER
• http://www.fda.gov/cber/dap/devlst.htm
• KSS/Blood Banking supplies consists of a wide variety of devices, some of which are:
• Blood temperature indicator
• Tube stripper
• Isotonic saline labeled for BB use
• Blood irradiation label
• Blood component separator
CC BBEE RR
Devices Reviewed at CBER (cont)• ZZZ/Unclassified was used for devices for
which a firm could identify a predicate, and therefore could submit a 510(k) but which had not been formally classified. This group also contains a wide variety of devices, such as:
• HLA reagents
• CMV test kits
• Instrument software
• Syphilis tests
• Platelet antigen/antibody tests
• Leukocyte removal filters
CC BBEE RR
What kinds of premarket device submissions does CBER review ?
Everything that CDRH doesBut fewer of them
INDs and BLAs
CC BBEE RR
Special Situations for IVDs* For diagnostic use only (except HIV and
retroviruses), CDRH regulates under MDAHIV and other retrovirus diagnostics
regulated by CBER under MDA For blood donor screening, CBER regulates
under MDA, i.e., 510(k)CMV
* As stated in the Intercenter Agreement
CC BBEE RR
Special Situations for IVDs (cont)* For diagnostic use AND blood donor screening,
CDRH is lead Center with each center reviewing their respective data sets under MDACMV
Required for use in blood donor testing, CBER regulates under the PHS ActBlood borne pathogen tests (IND/BLA)
• Syphilis is an exception (reviewed under 510(k))Immunohematology reagents (BLA)
CC BBEE RR
What are some of the public health issues that are unique to CBER ?
Ensuring safety and efficacy of biological therapeutic products Management of those products
Recalls Management of donors
Temporary deferral and subsequent re-entryPermanent deferralCounseling
Rapid response to emerging infectious agentsTSEsWest Nile VirusSARS
CC BBEE RR
What are some of the outside groups CBER deals with ?
Significant outside interactions with: Blood Products Advisory CommitteeAdvisory Committee on Blood Safety and AvailabilityPHS Blood
• FDA, CDC, NIH, DODCongressPublic perception of blood safetyPatient advocacy groups
CC BBEE RR
Scope of the Blood Industry
Whole Blood 13.9 million units
collected/yr 18 million components 8 million donors 3000 registered facilities 3.5 million recipients
Source Plasma 12 million units collected/yr Manufactured into 35
different plasma derivative products
1 million donors 80 licensed establishments
CC BBEE RR
What are some of the review issues that are important to CBER ?
Detection and identification of disease in a population of “normal, healthy adults”
Versus
Diagnosis of disease in a patient showing signs and symptoms of disease
Requires higher numbers of clinical trial samples to assure statistical significance
CC BBEE RR
What are some of the review issues that are important to CBER ?
Many of our products are Combination Products because they are linked by their labeling, i.e., a system
Licensed reagent(s) (biologicals)Accessory reagents (devices)Accessory instruments (devices)Accessory software (devices)Ancillary goods (devices)
• Pipettes
• Tubes
• Micro-well plates Others are combination products because of their packaging
Therapeutic biological in a syringe
CC BBEE RR
What are some of the procedural issues that are different at CBER ?
We currently do not respond by e-mail to incoming e-mails that contain proprietary or confidential information but are working on a secure e-mail system to allow us to do so.
We have different submission binding and filing formats.Please see SOPPs 8007 and 8110 at:http://www.fda.gov/cber/regsopp/regsopp.htm
We have a different address: FDA/CBER Document Control Center, HFM-99, Suite 200N 1401 Rockville Pike Rockville, MD 20852-1448
We usually need more than one copy; please send at least two or call ahead and ask.
CC BBEE RR
Recent CBER Process Changes (To Enhance the Review Process)
New priority courier service for regulatory documents New bar-coded tracking of regulatory documents Close collaboration with CDRH Least Burdensome training Active problem solving during first cycle, not just
problem finding Down delegation to Division Directors
CC BBEE RR
Recent CBER Process Changes (cont) Where possible, use CDRH policies Set internal goals in parallel with CDRH
ex. 60 day response for 510(k) IVD submissions Increased pre-submission meetings Device subcommittee of RMCC
CC BBEE RR
Is everything unique or different at CBER ?
ABSOLUTELY NOT ! We are subject to the same Congressional mandates as CDRH
FDAMAMDUFMA
We support the use of pre-submittal (Pre-IDE) meetingsCBER SOPP 8101.1
http://www.fda.gov/cber/regsopp/81011.htm We utilize:
Standards & guidancesScientific workshopsAdvisory committee recommendations
CC BBEE RR
How Do I Find a Predicate ? Go to CBER’s web site for list of cleared devices 1st
510(k) Blood Establishment Computer Software http://www.fda.gov/cber/products/510ksoft.htmSubstantially Equivalent 510(k) Device Information http://www.fda.gov/cber/efoi/510k.htm510(k) Device Applications (Cleared Since 1996) http://www.fda.gov/cber/dap/510kman.htm
If you can’t find one on ours, try CDRH’s website
CC BBEE RR
What about guidance documents ?Most general CDRH guidances are applicable Federal Register - FDA Modernization Act of 1997; List
of Documents Issued by the FDA That Apply to Medical Devices Regulated by CBER - 4/26/1999
Several CBER-specific guidances exist. The following are available at: http://www.fda.gov/cber/dap/devpubs.htm Federal Register - Medical Devices; Hematology and
Pathology Devices; Reclassification of Automated Blood Cell Separator Device Operating by Filtration Principle from Class III to Class II; Final rule - 2/28/2003
CC BBEE RR
CBER-specific guidances Draft Guidance for Industry: Premarket Notifications
[510(k)s] for In Vitro HIV Drug Resistance Genotype Assays: Special Controls - 8/28/2001
Draft Guidance for FDA Reviewers: Premarket Notification Submissions for Automated Testing Instruments Used in Blood Establishments - 8/3/2001
Guidance for FDA Reviewers: Premarket Notification Submissions for Blood and Plasma Warmers - 7/19/2001
Guidance for FDA Reviewers: Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices) - 7/19/2001
CC BBEE RR
CBER-specific guidances (cont) Guidance for FDA Reviewers: Premarket Notification
Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components - 7/19/2001
Draft Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA) – 7/15/1999
Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis – 2/17/1999
CC BBEE RR
CBER-specific guidances (cont)
These CBER-specific guidances are available at: http://www.fda.gov/cber/blood/bldguid.htm
Guidance for Industry: In the Manufacture and Clinical Evaluation of In Vitro Tests to Detect Nucleic Acid Sequences of Human Immunodeficiency Viruses Types 1 and 2 - 12/14/1999
Draft Guidance for Industry: Application of Current Statutory Authority to Nucleic Acid Testing of Pooled Plasma- 11/26/1999
CC BBEE RR
CBER-specific guidances (cont) Draft Guidance for Industry: In the Manufacture and
Clinical Evaluation of In Vitro Tests to Detect Nucleic Acid Sequences of Human Immunodeficiency Virus Type 1 - 7/10/1998
Guidance for Industry - The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use - 10/07/1997
Reviewer Guidance for a Premarket Notification Submission for Blood Establishment Computer Software - 1/13/1997
CC BBEE RR
CBER-specific guidances (cont) Draft Guideline for the Validation of Blood Establishment
Computer Systems - 9/28/1993
Draft Points to Consider in the Manufacture and Clinical Evaluation of In Vitro Tests to Detect Antibodies to the Human Immunodeficiency Virus Type 1 - 8/8/1989
CC BBEE RR
Contacting CBER About Submissions For pre-submission help:
Contact the person identified in the slides that follow based on the device you wish to discuss
If you cannot decide who to contact, contact the Center Ombudsman, Dr. Sheryl L. Lard-Whiteford
For post-submission help:Contact your RPM first (see acknowledgement letter)
• The RPM can set up conference call or meeting with the review team
Contact Division managementContact Office management (Dr. Mary Beth Jacobs for
OBRR)Contact the Center Ombudsman
CC BBEE RR
How to Contact CBER for Information Contact the Office of Communication, Training &
Manufacturers Assistance at: Phone 301-827-1800 or 800-835-4709E-mail [email protected] Web site http://www.fda.gov/cber/pubinquire.htm
See our current organization charts and lists at:
http://intranet.fda.gov/cber/admin/orgcht.htm Visit our web site: http://www.fda.gov/cber/ Guidance: http://www.fda.gov/cber/dap/devpubs.htm
CC BBEE RR
CBER Office of the Director Jesse L. Goodman, M.D., M.P.H., Center Director,
Previously Deputy for MedicineSpokesperson on West Nile Virus
Mark A. Elengold, Deputy Director for Operations Robert A. Yetter, Ph.D., Associate Director for
Review Management Diane Maloney, J.D., Associate Director for Policy Sheryl L. Lard-Whiteford, Ph.D., Associate
Director for Quality Assurance and CBER Ombudsman
CC BBEE RR
Office of Blood Research & Review Jay S. Epstein, M.D., Director Richard M. Lewis, Ph.D., Deputy Director Mark J. Weinstein, Ph.D., Associate Deputy Director John S. Finlayson, Ph.D., Associate Director for
Science Mary Elizabeth Jacobs, Ph.D., Associate Director for
Regulatory Affairs Edward Tabor, Ph.D., Associate Director for
Medical Affairs Linda A. Smallwood, Ph.D., Associate Director
for Policy (BPAC contact)
CC BBEE RR
Division of Blood Applications
Alan E. Williams, Ph.D., Director Elizabeth G. Callaghan, Deputy Director Sayah Nedjar, Ph.D., Chief, Regulatory
Program Management Branch Sheryl A. Kochman, Chief, Devices Review
Branch Elizabeth G. Callaghan, Chief (Acting) Blood
and Plasma Branch
CC BBEE RR
Division of Emerging & Transfusion Transmitted Diseases
Hira L. Nakhasi, Ph.D., Director Paul A. Mied, Ph.D., Deputy Director Indira K. Hewlett, Ph.D., Chief, Laboratory of
Molecular Biology Gerardo Kaplan, Ph.D., Chief, Laboratory of
Hepatitis & Related Emerging Agents David Asher, M.D., Chief, Laboratory of Bacterial,
Parasitic, & Unconventional Agents
CC BBEE RR
Division of Hematology Basil (Dov) Golding, M.D., Director (Acting) Andrew Chang, Ph.D., Deputy Director (Acting) Jaro Vostal, M.D., Ph.D., Chief (Acting),
Laboratory of Cellular Hemostasis Dorothy E. Scott, M.D., Chief (Acting),
Laboratory of Cellular Hematology Andrew Chang, Ph.D., Chief (Acting),
Laboratory of Hemostasis Toby A. Silverman, M.D., Chief, Clinical
Review Branch
CC BBEE RR
Office of Vaccines Research & Review Karen Midthun, M.D., Director William M. Egan, Ph.D., Deputy Director Norman W. Baylor, Ph.D., Associate Director for
Regulatory Policy Richard I. Walker, Ph.D., Director Division of
Bacterial, Parasitic & Allergenic Products Jerry P. Weir, Ph.D., Director, Division of Viral
Products Karen L. Goldenthal, M.D., Division of Vaccines &
Related Products Applications
CC BBEE RR
Office of Cellular, Tissue, & Gene Therapies
Philip D. Noguchi, M.D., Director (Acting) Joyce L. Frey-Vasconcells, Ph.D., Deputy Director
(Acting)Andrea Wright, Regulatory Management Staff
Raj K. Puri, M.D., Ph.D., Director (Acting), Division of Cellular & Gene Therapies
Cynthia A. Rask, M.D., Director (Acting), Division of Clinical Evaluation & Pharmacology/Toxicology
Ruth Solomon, M.D., Director (Acting), Division of Human Tissues
CC BBEE RR
Who Does What ? Office of Blood Research & Review (OBRR)
Division of Blood Applications (DBA)Devices Review Branch
• Immunohematology/HLA reagents, controls, instruments, and accessories
• Blood Establishment Computer Software (BECS)
• Meeting requests for the aboveCall Sheryl Kochman or staff at 301-827-3503
CC BBEE RR
Who Does What ? Office of Blood Research & Review (OBRR)(cont)
Division of Blood Applications (DBA)(cont)Regulatory Project Management Branch
• Blood collection, mixing, weighing, storage systems
• Management and tracking of the reviews• Meeting requests for all OBRR (except DRB)
submissionsCall Dr. Sayah Nedjar or staff at 301-827-5307
CC BBEE RR
Who Does What ? Office of Blood Research & Review (OBRR) (cont)
Division of Emerging & Transfusion Transmitted Diseases (DETTD)
• Blood borne pathogen reagents, kits, instruments
• HIV diagnostics, viral load test kits• West Nile Virus• TSEs
Call Dr. Sayah Nedjar or staff at 301-827-5307
CC BBEE RR
Who Does What ? Office of Blood Research & Review (OBRR) (cont)
Division of Hematology (DH)• Blood containers, cell separators, processing
systems• IVDs for platelet antigen/antibody testing• Bacterial detection systems• Cord/Stem cell collection, processing system
•Minimally manipulatedCall Dr. Sayah Nedjar or staff at 301-827-5307
CC BBEE RR
Who Does What ? Office of Cellular, Tissue & Gene Therapies (OCTGT)
Cord/Stem cell collection, processing system
• More than minimally manipulatedCall Dr. Stephanie L. Simek at 301-827-6536
Office of Vaccines Research & Review (OVRR)Division of Vaccines & Related Products (DVRPA)
• Endotoxin testing supplies
(The kits themselves are licensed biologicals)Call Dr. Paul Richman at 301-827-3070
CC BBEE RR
CBER Device Submissions Received*
FY00 FY01 FY02
PMAs (Traditional) 3 3 1
PMSs (Traditional) 5 8 5
510(k)s (All Types) 34 37 42
BLAs (Original) 4 2 2
BLSs (Efficacy) 0 0 0
BLSs (Manufacturing, PAS) 124 47 35
*Includes RTAs/RTFs, Transfers, Withdrawals
CC BBEE RR
CBER Device Submissions Received* (from 10/1/02 – 3/31/03)
FY 03PMAs (Traditional) 1PMSs (180 Day) 1510(k)s (All Types) 35BLAs (Original, Std) 0BLSs (Efficacy) 3BLSs (Manufacturing, PAS) 31
ALL MDUFMA FY 05 GOALS MET*
*Data as of 4/15/03
CC BBEE RR
510(k)s Received
0
5
10
15
20
25
30
35
40
45
FY00 FY01 FY02 FY03 (6 mo)
TraditionalAbbreviatedSpecial
CC BBEE RR
CBER 510(k)s – Current Status*(Receipts from 10/1/02 – 3/31/03)
Under 1st Cycle
510(k) Type Rec’d SE NSE Other Review Complete
Traditional 21 10 0 3 5 3
Abbreviated 6 3 0 0 2 1
Special 8 7 1 0 0 0
Total 35 20 1 3 7 4
*All data as of 4/15/03
CC BBEE RR
CBER 510(k) Cycles*(from Receipt to Final Action)
Under 1st Cycle
510(k) Type (SE/NSE) (Average)** Review Completed
Traditional 10 1.1 5 3
Abbreviated 3 1.3 2 1
Special 8 1.0 0 0
Total 21 1.1 7 4
* All data as of 4/15/03**Cycles will increase with completion of pendings
CC BBEE RR
Time to Final Decision: FY 02*(510(k) Receipt Cohort from 10/1/01 – 9/30/02)
FDA Time Total Time Cycles
510(k) Type n (Days, Ave) (Days, Ave) (Average)
Traditional 18 141.2 175.5 1.89
Abbreviated 7 124.4 165.3 2.00
Special 4 38.8 50.0 1.50
Total 29 123.0 155.7 1.86
* SE/NSEs Only; Data as of 4/15/03
CC BBEE RR
Time to Final Decision: Current*(510(k) Receipt Cohort from 10/1/02 – 3/31/03)
FDA Time Total Time
510(k) Type n (Days, Ave)** (Days, Ave)**
Traditional 10 58.8 61.0
Abbreviated 3 60.0 69.3
Special 8 19.9 19.9
Total 21 44.1 46.5
* SE/NSEs Only; Data as of 4/15/03
**Times will increase with completion of pendings
CC BBEE RR
Acknowledgements Dr. Mary Beth Jacobs, Ph.D., CBER/OBRR/IOD Michael A. Calabro, Ph.D.; CBER/OBRR/IOD